Keros Therapeutics

KROS

Market cap $432M

LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026.

LEXINGTON, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:

KROS investors eye pipeline updates as rinvatercept advances in DMD and Takeda-backed elritercept hits milestones ahead of Q4 results.

Keros Therapeutics KROS is a clinical-stage biopharmaceutical company developing innovative therapies for patients with disorders caused by abnormal signaling within the transforming growth factor-beta (TGF-β) protein family.

KROS is advancing KER-065 for Duchenne muscular dystrophy, with orphan drug status and a phase II trial planned for early 2026.

Keros Therapeutics sharpens focus on KER-065 for DMD, cuts staff 45%, shelves cibotercept, and plans a phase II trial in Q1 2026 with cash runway into 2028.

KROS shares are up 85.6% in a year, driven by a strategic review and pipeline progress led by KER-065 and elritercept, which have fueled investor enthusiasm.

AES, BWA, ENS, PCG and KROS screen as low P/B stocks with Buy ratings, offering value-focused opportunities as 2025 comes to a close.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?

Keros Therapeutics (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).